Vanderbilt Center for Antibody Therapeutics (VCAT) Archive

May 15, 2015

VU lands $9 million NIH grant to design better flu vaccines

Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.

By Bill Snyder
April 8, 2015

VU joins national effort to speed Ebola therapy testing

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

By Bill Snyder
February 26, 2015

Studies show human antibodies can fight lethal Marburg virus

Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola.

By Bill Snyder
January 29, 2015

Core facilities key driver of VUMC research gains

During the past five years, Vanderbilt University Medical Center has become a leader in “personalized medicine,” the use of genomic information to individualize patient care.

By Bill Snyder
December 18, 2014

Year in review: 2014 a year of accomplishments, milestones for VUMC

The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2014.

By Doug Campbell
October 21, 2014

Vanderbilt’s Brown, Crowe elected to IOM

By Bill Snyder
September 24, 2014

Alexander’s visit highlights efforts to confront Ebola

Don’t panic over Ebola. But don’t ignore it, either. That was the take-home message for U.S. citizens from a “mini-hearing” held by U.S. Sen. Lamar Alexander, R-Tenn., at Vanderbilt University Medical Center on Wednesday with researchers and health officials from Vanderbilt and the State of Tennessee.
By Bill Snyder
September 18, 2014

Initiative seeks to develop therapies to combat Ebola

Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.
By Bill Snyder
September 11, 2014

Engelhardt lands stem cell transplant research grant

Up to 60 percent of patients who receive a stem cell transplant using cells from another donor will develop post-transplant diabetes mellitus, which can increase the rate of complications and death after the procedure.
By VUMC News and Communications
May 1, 2014

Cutting-edge research to be showcased in May

By Bill Snyder
April 7, 2014

Vanderbilt Vaccine Center joins global task force to address urgent viral threat

By John Howser
March 6, 2014

Multi-center effort targets lethal Ebola, Marburg viruses

Vanderbilt University researchers are collaborating in a multi-center, federally-funded project to develop ways to treat and prevent the highly lethal Ebola and Marburg virus infections.
By Bill Snyder
February 5, 2014

Discovery may pave way for RSV vaccine

Vanderbilt University scientists have contributed to a major finding, reported this week in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.
By Bill Snyder